Natco Pharma Limited(BSE:524816 NSE:NATCOPHARM) ,Company Snapshot, Recent Developments, Latest News, Financials, Price Charts, Ratios, Contact Information

Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals

Home

News Centre

IPO

Markets	Companies	Research	Industries	E-Mail Page

my Last 5 Scrips
Company	BSE Price(Rs)	% Chg
Tata Stl	312.80	10.59
State Ba	2152.20	1.10
Tata Mot	287.35	1.19
Bhel	191.85	2.02
Hindalco	108.90	0.05
Clear All	Clear Last

NSE Live
Nifty Live Prices Live Quotes Top Gainers/Losers Top 10 Turnover No Delivery Stocks

BSE Live
BSE30 Live Prices Live Quotes Top Gainers/Losers Top 10 Turnover No Delivery Stocks

Market Pulse
Leaders Laggards FII Activity Mutual Fund Activity Meetings

Results Watch
Results Calendar Results Announced

IPO Watch

Company
Snapshots Quotes Charts Financials Recent News Broker Research Meetings Research Tutorial Discussion Forum

Research
Research Reports

Sector Watch

Economy Watch

Snapshot-Natco Pharma Limited

Natco Pharma Limited

Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:524816	NSE:NATCOPHARM	Bloomberg:NTCPH@IN	Reuters:NATP.BO
Market Lot: 1	Face Value: 10	ISIN Demat: INE987B01018

Quotes	Snapshot	Charts	Financials	Research	Recent News
Peer Group	AGM/AM	MF Holding	Discussion Forum	BSE/NSE Notices	BSE/NSE Deals

Recent Developments
19-DEC-12 Drugmaker Natco Pharma has received the US FDA approval, of its Abbreviated New Drug Application (ANDA) for Lansoprazole Delayed Release Capsules, USP, 15 mg and 30 mg. for the prescription market. 25-JUN-12 The US District Court for the Southern District of New York has upheld the contention of Teva Pharmaceuticals (Teva) that NATCO Pharma`s (the company) abbreviated new drug application (ANDA) for the generic version of Copaxone ?... More..
Business Profile	Future Plans

One To One

Latest News

Natco Pharma surges 5.3% on USFDA nod to launch Lansoprazole -IRIS 19-Dec-12

Brief Financials (in Rs. Mn.)

Period ending (months)	31-Dec-2012(9)	31-Mar-2012 (12)	31-Mar-2011 (12)
Net sales	3861.00	4304.20	3382.60
Other Income	79.50	32.70	7.20
Total Income	3940.50	4336.90	3389.80
Cost of goods sold	2930.30	3500.20	2799.40
OPBDIT	1010.20	836.70	590.40
PAT	664.20	621.30	521.20
Gross Block	-	-	-
Equity capital	313.70	311.50	281.50
EPS (Rs.)	-	21.39	18.52
DPS (Rs.)	-	-	-
BV (Rs.)	-	-	-
P/E range (x)	-	9.22 - 16.90	7.21 - 19.33
Debt / Equity (x)	-	-	-
Operating margin (% of OI)	25.6	19.3	17.4
Net margin (% of OI)	16.9	14.3	15.4